A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
How does the micro-cap biotech now finance a 700-patient phase 3 study?
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.